NAMS

Company Overview — What Does NewAmsterdam Pharma Co N.V. Do?

NewAmsterdam Pharma Co N.V. (NAMS) is a mid-cap company in the Healthcare sector, operating within the Pharmaceutical Products industry. The stock has a market capitalization of $3.8B, making it a notable participant in its sector. Investors researching NAMS stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Pharmaceutical Products space.

NewAmsterdam Pharma Co N.V. (NAMS) Stock Rating — Hold (April 2026)

As of April 2026, NewAmsterdam Pharma Co N.V. receives a Hold rating with a composite score of 39.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.NAMS ranks #1,603 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NewAmsterdam Pharma Co N.V. ranks #144 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NAMS Stock Price and 52-Week Range

NewAmsterdam Pharma Co N.V. (NAMS) currently trades at $34.76. The stock lost $0.31 (0.9%) in the most recent trading session. The 52-week high for NAMS is $42.00, which means the stock is currently trading -17.2% from its annual peak. The 52-week low is $14.06, putting the stock 147.2% above its annual trough. Recent trading volume was 547K shares, suggesting relatively thin trading activity.

Is NAMS Overvalued or Undervalued? — Valuation Analysis

NewAmsterdam Pharma Co N.V. (NAMS) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.70x, versus the sector average of 2.75x. The price-to-sales ratio is 75.58x, compared to 1.66x for the average Healthcare stock.

At current multiples, NewAmsterdam Pharma Co N.V. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NewAmsterdam Pharma Co N.V. Profitability — ROE, Margins, and Quality Score

NewAmsterdam Pharma Co N.V. (NAMS) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -21.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -18.9% versus the sector average of -33.1%.

On a margin basis, NewAmsterdam Pharma Co N.V. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -4608.0% (sector: -66.1%). Net profit margin stands at -5541.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -84.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NAMS Debt, Balance Sheet, and Financial Health

NewAmsterdam Pharma Co N.V. has a debt-to-equity ratio of 13.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.88x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $538M.

NAMS has a beta of 1.12, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NewAmsterdam Pharma Co N.V. is 43/100, reflecting average volatility within the normal range for its sector.

NewAmsterdam Pharma Co N.V. Revenue and Earnings History — Quarterly Trend

In TTM 2026, NewAmsterdam Pharma Co N.V. reported revenue of $52M and earnings per share (EPS) of $-1.72. Net income for the quarter was $-146M. Gross margin was 100.0%. Operating income came in at $-185M.

In FY 2025, NewAmsterdam Pharma Co N.V. reported revenue of $23M and earnings per share (EPS) of $-1.72. Net income for the quarter was $-204M. Revenue grew -50.6% year-over-year compared to FY 2024. Operating income came in at $-226M.

In Q3 2025, NewAmsterdam Pharma Co N.V. reported revenue of $348,000 and earnings per share (EPS) of $-0.61. Net income for the quarter was $-72M. Revenue grew -98.8% year-over-year compared to Q3 2024. Operating income came in at $-55M.

In Q2 2025, NewAmsterdam Pharma Co N.V. reported revenue of $19M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-17M. Revenue grew 740.1% year-over-year compared to Q2 2024. Operating income came in at $-36M.

Over the past 8 quarters, NewAmsterdam Pharma Co N.V. has demonstrated a growth trajectory, with revenue expanding from $2M to $52M. Investors analyzing NAMS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NAMS Dividend Yield and Income Analysis

NewAmsterdam Pharma Co N.V. (NAMS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NAMS Momentum and Technical Analysis Profile

NewAmsterdam Pharma Co N.V. (NAMS) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

NAMS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NewAmsterdam Pharma Co N.V. (NAMS) ranks #144 out of 838 stocks based on the Blank Capital composite score. This places NAMS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NAMS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NAMS vs S&P 500 (SPY) comparison to assess how NewAmsterdam Pharma Co N.V. stacks up against the broader market across all factor dimensions.

NAMS Next Earnings Date

No upcoming earnings date has been announced for NewAmsterdam Pharma Co N.V. (NAMS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NAMS? — Investment Thesis Summary

NewAmsterdam Pharma Co N.V. presents a balanced picture with arguments on both sides. The quality score of 27/100 flags below-average profitability. The value score of 27/100 indicates premium valuation.

In summary, NewAmsterdam Pharma Co N.V. (NAMS) earns a Hold rating with a composite score of 39.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NAMS stock.

Related Resources for NAMS Investors

Explore more research and tools: NAMS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NAMS head-to-head with peers: NAMS vs AZN, NAMS vs SLGL, NAMS vs VMD.